NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NKTR-255’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NKTR-255 is under development for the treatment of relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, metastatic urothelial cancer, cancer immunotherapies, metastatic head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC), colon carcinoma, metastatic cervical cancer, metastatic anal squamous cell carcinoma, metastatic cutaneous squamous cell carcinoma, Ewing sarcoma, osteosarcoma, neuroblastoma, Burkitt lymphoma, diffuse large b-cell lymphoma, follicular lymphoma, non-small cell lung cancer, primary mediastinal large b-cell lymphoma and infectious disease. It is a recombinant protein. It is administered through intravenous route. It is developed based on polymer conjugation technology. It was also under development for lung cancer.
Nektar Therapeutics overview
Nektar Therapeutics (Nektar) discovers and develops novel therapeutic drug candidates based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs. The company’s technology platforms offer a wide range of functional attributes, which optimizes and enhances the profile of a wide range of molecules including large classes of drugs targeting numerous disease areas. The company’s products focus on various disease areas including cancer, pain, infections, and immunology, among others. Its research and development involve peptides, proteins, antibodies, small molecule drugs, and other potential biological drug candidates. Nektar Therapeutics is headquartered in San Francisco, California, the US.
For a complete picture of NKTR-255’s drug-specific PTSR and LoA scores, buy the report here.